In Vivo Confocal Microscopic Analysis of Corneal Nerve Changes After ProKera Slim® for Dry Eye

NCT ID: NCT02764814

Last Updated: 2016-11-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-07-31

Study Completion Date

2016-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Prospective controlled pilot study to compare the outcome of ProKera® (PK) and conventional treatment in patients with moderate to severe Dry Eye Disease (DED)

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Dry Eye Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment

subjects receiving cryopreserved amniotic membrane

Group Type ACTIVE_COMPARATOR

Cryopreserved amniotic membrane

Intervention Type OTHER

subjects will receive cryopreserved amniotic membrane

Control

no intervention

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cryopreserved amniotic membrane

subjects will receive cryopreserved amniotic membrane

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

ProKera Slim

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subjects with moderate to severe DED (Grade 2-4 DEWS)
* Age range: 21 years and older.
* Both genders and all ethnic groups comparable with the local community.
* Subjects able to understand and willing to sign a written informed consent.
* Subjects able and willing to cooperate with investigational plan.
* Subjects able and willing to complete postoperative follow-up.

Exclusion Criteria

* Symblepharon or lid abnormality preventing ProKera placement.
* Ocular infection within 14 days prior to study entry.
* Active ocular allergies.
* Previous ocular surgery or injury within 3 months before enrollment.
* Previous brain surgery, or Trigeminal nerve damage.
* Other conditions that may affect corneal nerves such as diabetes, thyroid disorders.
* Contact lens wearers.
* Pregnancy or subject expecting to be pregnant.
* Inability or unwillingness of subject to give written informed consent.
* Subjects with known intolerance to PK.
* Subjects use concomitant therapy that affects tear functions or ocular surface integrity.
* Subjects currently engaged in another clinical trial.
Minimum Eligible Age

21 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

BioTissue Holdings, Inc

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Thomas John, MD

Role: PRINCIPAL_INVESTIGATOR

Thomas John Vision Institute

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Thomas John Vision Institute, P.C.

Tinley Park, Illinois, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

John T, Tighe S, Sheha H, Hamrah P, Salem ZM, Cheng AMS, Wang MX, Rock ND. Corneal Nerve Regeneration after Self-Retained Cryopreserved Amniotic Membrane in Dry Eye Disease. J Ophthalmol. 2017;2017:6404918. doi: 10.1155/2017/6404918. Epub 2017 Aug 15.

Reference Type DERIVED
PMID: 28894606 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

P014-03

Identifier Type: -

Identifier Source: org_study_id